Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, today announced that the first patient has been dosed in a U.S. multi-center, Phase I clinical trial, evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 欧洲杯买球网, the company’s proprietary anti-CD39 monoclonal antibody (mAb), that is being developed for the treatment of advanced solid tumors (NCT05075564). Elpiscience received U.S. Food and Drug Administration (FDA) IND clearance for 欧洲杯买球网 in September 2021.

“We are very pleased to see 欧洲杯买球网 enter clinical trial testing in the United States,” said Steve Chin, CMO of Elpiscience. “This is an important milestone for Elpiscience as we seek to develop innovative and differentiated cancer immunotherapies. We look forward to announcing additional clinical milestones throughout 2022 as Elpiscience expands its pipeline with a steadfast commitment to advance at least one innovative molecule into the clinic each year.”

欧洲杯买球网 has demonstrated highly potent single-agent anti-tumor activity showing significant reduction in tumor size and weight in in-vivo pharmacology studies.

About 欧洲杯买球网:

欧洲杯买球网 is an anti-CD39 mAb designed to promote anti-tumor immunity. CD39 is a key enzyme regulating the production of adenosine, a critical immune suppressor. By blocking CD39 function, 欧洲杯买球网 also stabilizes pro-inflammatory extracellular ATP (eATP) and restores anti-tumor immunity within the tumor microenvironment. 欧洲杯买球网 demonstrated highly potent single-agent anti-tumor activity in in-vivo pharmacology studies.

About Elpiscience:

Elpiscience is a clinical stage biopharmaceutical company focused on innovating and developing next-generation immunotherapy. The company has a robust pipeline of globally innovative molecules, covering wide range of targets in immuno-oncology. It has four molecules in clinical trials, including 欧洲杯买球网, ES101, 欧洲杯买球网APP, and 欧洲杯买球网. Founded and managed by a team of biopharma industry leaders and scientists, Elpiscience is backed by renowned investors including, Lilly Asia Ventures, Hillhouse Capital, Hyfinity Investments, Greater Bay Area Homeland Development Fund, CDH, DYEE Capital and Cormorant Asset Management. Elpiscience endeavors to advance at least one innovative molecule into the clinic each year to benefit cancer patients worldwide.